No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 1 | 1 | 1 | 1 | N/A | N/A |
| Operating profit | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | $m | 0 | -0 | -0 | 0 | -0 | -0 | N/A | N/A |
| EPS reported | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | Locked | Locked | Locked |
| Environmental score | Locked | Locked | Locked |
| Social score | Locked | Locked | Locked |
| Governance score | Locked | Locked | Locked |
| Risk rating | Locked | Locked | Locked |
Company overview
Herborium Group, Inc. operates as a specialized firm in botanical therapeutics, focusing on the creation, licensing, and commercialization of its unique, plant-based medicinal goods for both general consumers and healthcare professionals. Its product range includes dermatological solutions like AcnEase, an herbal treatment designed to alleviate symptoms associated with hormonal acne and various forms of Rosacea. The company also offers the AcnEase Skin Management System, intended to diminish acne marks and scars. Furthermore, Herborium provides non-prescription sexual health and performance products. These serve as alternatives for specific sexual dysfunctions that may arise from cardiovascular conditions, the use of antidepressants, or surgical procedures such as hysterectomies. The company also offers energy-boosting products, notably Lasting Energy. This herbal supplement aims to reduce hangover effects, counteract jet lag, and address general energy depletion caused by intense physical activities, high stress levels, prolonged sexual engagements, or other enduring or temporary physical demands. Additional products in its portfolio include the Liver Activator Series for managing liver damage; ProstAid, a natural remedy specifically formulated for Benign Prostate Hyperplasia (BPH); and CardioVitae, a fermentation-based product utilizing a Lucidium-derived cell line to target cardio-pulmonary insufficiencies. Herborium Group, Inc. distributes its products across the United States, the United Kingdom, and mainland Europe, utilizing a network of distributors, specialty retailers, and its e-commerce platform. The company was founded in 2000 and has its principal office located in Fort Lee, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Herborium Group, Inc. operates as a specialized firm in botanical therapeutics, focusing on the creation, licensing, and commercialization of its unique, plant-based medicinal goods for both general consumers and healthcare professionals. Its product range includes dermatological solutions like AcnEase, an herbal treatment designed to alleviate symptoms associated with hormonal acne and various forms of Rosacea. The company also offers the AcnEase Skin Management System, intended to diminish acne marks and scars. Furthermore, Herborium provides non-prescription sexual health and performance products. These serve as alternatives for specific sexual dysfunctions that may arise from cardiovascular conditions, the use of antidepressants, or surgical procedures such as hysterectomies. The company also offers energy-boosting products, notably Lasting Energy. This herbal supplement aims to reduce hangover effects, counteract jet lag, and address general energy depletion caused by intense physical activities, high stress levels, prolonged sexual engagements, or other enduring or temporary physical demands. Additional products in its portfolio include the Liver Activator Series for managing liver damage; ProstAid, a natural remedy specifically formulated for Benign Prostate Hyperplasia (BPH); and CardioVitae, a fermentation-based product utilizing a Lucidium-derived cell line to target cardio-pulmonary insufficiencies. Herborium Group, Inc. distributes its products across the United States, the United Kingdom, and mainland Europe, utilizing a network of distributors, specialty retailers, and its e-commerce platform. The company was founded in 2000 and has its principal office located in Fort Lee, New Jersey.